Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics... Show more
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ALNY advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day RSI Indicator for ALNY moved out of overbought territory on March 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on April 04, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ALNY as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on April 04, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
ALNY moved below its 50-day moving average on April 04, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALNY crossed bearishly below the 50-day moving average on April 08, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The 50-day moving average for ALNY moved below the 200-day moving average on April 08, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ALNY broke above its upper Bollinger Band on March 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALNY entered a downward trend on March 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALNY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ALNY's P/B Ratio (434.783) is very high in comparison to the industry average of (12.883). P/E Ratio (0.000) is within average values for comparable stocks, (61.746). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.735). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (12.755) is also within normal values, averaging (239.728).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a developer of therapeutics based on RNA interference
Industry Biotechnology
A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with IONS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then IONS could also see price increases.
Ticker / NAME | Correlation To ALNY | 1D Price Change % | ||
---|---|---|---|---|
ALNY | 100% | -3.70% | ||
IONS - ALNY | 52% Loosely correlated | -7.47% | ||
ARGX - ALNY | 42% Loosely correlated | -0.19% | ||
ARWR - ALNY | 34% Loosely correlated | -2.54% | ||
GOSS - ALNY | 32% Poorly correlated | -3.97% | ||
RARE - ALNY | 32% Poorly correlated | -3.36% | ||
More |